Inventor · disambiguated record
Qing Dong
Also filed as: DONG QING
73 granted patents·39 pending applications·589 citations·filing 1999–2025
99Inventor score
Files withTAKEDA PHARMACEUTICAL16XINTHERA INC15DONG QING10JIANGSU HENGRUI MEDICINE CO8Shanghai hengrui pharmaceutical co ltd7
Top patents by PatentIndex Score
112 records- 0196US11795173B1Substituted pyridines as PARP1 inhibitorsXINTHERA INC·Filed 2023·Granted Oct 24, 2023·5 cites·18 claims
- 0296US11591331B2PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2022·Granted Feb 28, 2023·6 cites·21 claims
- 0396US11053219B2Substituted pyridines as TYK2 inhibitorsFRONTHERA U S PHARMACEUTICALS LLC·Filed 2020·Granted Jul 6, 2021·9 cites·57 claims
- 0496US8119655B2Kinase inhibitorsDONG QING·Filed 2006·Granted Feb 21, 2012·59 cites·17 claims
- 0595US12006322B2Substituted pyridines as PARP1 inhibitorsXINTHERA INC·Filed 2023·Granted Jun 11, 2024·2 cites·4 claims
- 0695US11680056B2MK2 inhibitors and uses thereofXINTHERA INC·Filed 2022·Granted Jun 20, 2023·3 cites·28 claims
- 0795US7569571B2Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulatorsNOVARTIS AG·Filed 2004·Granted Aug 4, 2009·104 cites·5 claims
- 0894US11802128B2Azetidine and pyrrolidine PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted Oct 31, 2023·3 cites·15 claims
- 0994US11685719B2Pyridinone MK2 inhibitors and uses thereofXINTHERA INC·Filed 2022·Granted Jun 27, 2023·3 cites·30 claims
- 1093US11939329B2PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted Mar 26, 2024·2 cites·5 claims
- 1193US6297260B1Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of useNITROMED INC·Filed 1999·Granted Oct 2, 2001·113 cites·23 claims
- 1292US11964964B2Thyroid hormone receptor agonists and uses thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2019·Granted Apr 23, 2024·8 cites·18 claims
- 1392US11731956B2Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitorsALUMIS INC·Filed 2022·Granted Aug 22, 2023·1 cites·2 claims
- 1492US8440689B2Fused heteroaromatic pyrrolidinonesARIKAWA YASUYOSHI·Filed 2010·Granted May 14, 2013·23 cites·28 claims
- 1592US7713973B2Kinase inhibitorsTAKEDA PHARMACEUTICAL·Filed 2005·Granted May 11, 2010·21 cites·31 claims
- 1691US6593347B2Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of useNITROMED INC·Filed 2001·Granted Jul 15, 2003·43 cites·28 claims
- 1790US11040972B2Autotaxin inhibitors and uses thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2020·Granted Jun 22, 2021·2 cites·21 claims
- 1890US9527851B2Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2012·Granted Dec 27, 2016·17 cites·21 claims
- 1989US8288536B2Kinase inhibitorsDONG QING·Filed 2010·Granted Oct 16, 2012·14 cites·8 claims
- 2088US10428074B2Pyrrole heteroaryl ring derivative and method of use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Oct 1, 2019·6 cites·23 claims
- 2187US12006306B2Substituted pyridazines as TYK2 inhibitorsALUMIS INC·Filed 2021·Granted Jun 11, 2024·1 cites·16 claims
- 2286US9987707B23D print apparatus and method utilizing friction stir weldingDONG XIAO·Filed 2016·Granted Jun 5, 2018·8 cites·10 claims
- 2386US8268819B2Hexahydrooxazinopterine compoundsJIN BOHAN·Filed 2012·Granted Sep 18, 2012·11 cites·8 claims
- 2485US12421241B2Substituted pyridines as PARP1 inhibitorsXINTHERA INC·Filed 2024·Granted Sep 23, 2025·0 cites·4 claims
- 2585US12351572B2Substituted 1,2,4-triazoles as TYK2 inhibitorsALUMIS INC·Filed 2023·Granted Jul 8, 2025·0 cites·7 claims
- 2685US9586947B2Imidazoline derivatives, preparation methods thereof, and their applications in medicineShanghai hengrui pharmaceutical co ltd·Filed 2013·Granted Mar 7, 2017·9 cites·21 claims
- 2785US8791107B2N-substituted oxazinopteridines and oxazinopteridinonesCHANG EDCON·Filed 2012·Granted Jul 29, 2014·10 cites·13 claims
- 2884US8163755B2Hexahydrooxazinopterine compoundsJIN BOHAN·Filed 2010·Granted Apr 24, 2012·9 cites·17 claims
- 2983US2023295171A1Fused heteroaromatic pyrrolidinonesCALITHERA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3082US11987574B2MK2 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted May 21, 2024·0 cites·22 claims
- 3182US8030317B2MAPK/ERK kinase inhibitorsTAKEDA PHARMACEUTICAL·Filed 2007·Granted Oct 4, 2011·4 cites·18 claims
- 3279US12384780B2PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2024·Granted Aug 12, 2025·0 cites·2 claims
- 3379US12060343B2Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitorsALUMIS INC·Filed 2022·Granted Aug 13, 2024·0 cites·6 claims
- 3479US9388133B2Pyrrole sulfonamide derivative, preparation method for same, and medical application thereofJIANGSU HANSOH PHARMACEUTICAL CO LTD·Filed 2013·Granted Jul 12, 2016·5 cites·21 claims
- 3578US10537555B2Complex of angiotensin receptor antagonist and neutral endopeptidase inhibitorCHENGDU EASTON BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Jan 21, 2020·2 cites·19 claims
- 3678US9108970B2Fused heteroaromatic pyrrolidinonesTAKEDA PHARMACEUTICAL·Filed 2013·Granted Aug 18, 2015·2 cites·31 claims
- 3777US12139462B2Pyridinone MK2 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted Nov 12, 2024·0 cites·30 claims
- 3876US10711000B2Autotaxin inhibitors and uses thereofFRONTHERA U S PHARMACEUTICALS LLC·Filed 2019·Granted Jul 14, 2020·1 cites·20 claims
- 3976US9637484B2Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted May 2, 2017·5 cites·20 claims
- 4075US9181255B2Fused heteroaromatic pyrrolidinones as SYK inhibitorsARIKAWA YASUYOSHI·Filed 2010·Granted Nov 10, 2015·2 cites·28 claims
- 4175US7011676B2Flat knitted stent and method of making the sameSCIMED LIFE SYSTEMS INC·Filed 2002·Granted Mar 14, 2006·56 cites·35 claims
- 4274US12358899B2Thyroid hormone receptor agonists and uses thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2024·Granted Jul 15, 2025·0 cites·13 claims
- 4374US8609622B2C-aryl glucoside derivatives, preparation process and pharmaceutical use thereofYANG FANGLONG·Filed 2011·Granted Dec 17, 2013·6 cites·26 claims
- 4474US7696218B2Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinaseTAKEDA SAN DIEGO INC·Filed 2007·Granted Apr 13, 2010·1 cites·15 claims
- 4573US10364234B2Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2015·Granted Jul 30, 2019·1 cites·16 claims
- 4673US10005781B2Pyrazolopyrimidone or pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Jun 26, 2018·2 cites·20 claims
- 4772US8022057B2MAPK/ERK kinase inhibitorsTAKEDA PHARMACEUTICAL·Filed 2008·Granted Sep 20, 2011·1 cites·82 claims
- 4871US8088783B2MAPK/ERK kinase inhibitorsDONG QING·Filed 2011·Granted Jan 3, 2012·1 cites·6 claims
- 4971US7943626B2Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinaseTAKEDA PHARMACEUTICAL·Filed 2010·Granted May 17, 2011·1 cites·6 claims
- 5071US2024299291A1Ophthalmic preparation administered by eye drops and used for preventing and treating dry macular degeneration and retinal light damageCHENGDU RUIMU BIOPHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
Showing the top 50 of 112 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Qing Dong files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →